Superluminal lands $60m Series B to take genetic obesity drug into human trials

Superluminal Medicines has closed an oversubscribed $60 million Series B financing led by BVF Partners to advance its first internally owned drug candidate into human testing, turning an artificial-intelligence-enabled discovery platform into a clinical biotechnology company. New investors Deep Track Capital and Perceptive Advisors joined existing backers including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Cooley and Gaingels. The proceeds will primarily support a Phase 1 study expected to begin by the end of 2026 for Superluminal’s selective, biased melanocortin-4 receptor agonist targeting rare genetic forms of obesity and hypothalamic obesity, while also funding additional GPCR programs and further development of its Hyperloop discovery platform. The financing gives Superluminal a substantial clinical runway, but it also places the company against a commercially validated competitor because Rhythm Pharmaceuticals already sells the MC4R agonist IMCIVREE and generated $71.3 million from that franchise during the second quarter.

The financing is notable because Superluminal is already closely connected to two of the most influential companies in technology and obesity medicine. NVIDIA’s venture arm remains an investor, while Eli Lilly has backed the company and separately signed a collaboration worth as much as $1.3 billion to discover small molecules against undisclosed GPCR targets relevant to obesity and cardiometabolic disease. The newly financed MC4R program is part of Superluminal’s own pipeline rather than simply one of Lilly’s partnered targets, allowing the biotech to preserve substantially greater economics if the medicine ultimately succeeds.

How much capital has Superluminal Medicines assembled before reaching Phase 1?

The $60 million Series B follows a $33 million seed financing announced when Superluminal launched in 2023 and a $120 million Series A completed in 2024. Those three disclosed equity rounds total approximately $213 million before considering undisclosed upfront and near-term payments connected with the Eli Lilly collaboration. The company has therefore attracted more private capital before dosing its lead program than many biotechnology companies carry after entering the clinic, reflecting investor willingness to finance both the underlying discovery platform and the obesity opportunity surrounding MC4R biology.

The investor composition is equally informative. BVF Partners led the latest financing, while specialist healthcare investors Deep Track Capital, Perceptive Advisors and RA Capital Management sit beside technology-oriented NVentures and strategic pharmaceutical investor Eli Lilly. Such syndicates can provide more than money because specialist investors can support later financing and public-market preparation, while pharmaceutical relationships can become future development or transaction opportunities.

No valuation was disclosed for the Series B, preventing any reliable calculation of investor dilution or the price being placed on Superluminal’s lead candidate. That missing number matters because $60 million can be a highly attractive financing if completed at a strong valuation or a substantial ownership transfer if investors demanded aggressive terms before first-in-human data. The round therefore establishes capital strength without revealing how much of the company existing shareholders gave up to obtain it.

What is Superluminal trying to improve on an already validated MC4R drug class?

The melanocortin-4 receptor is a central regulator of appetite, energy expenditure and body weight, making it particularly relevant in rare obesity disorders where the pathway is genetically impaired or disrupted by hypothalamic injury. Superluminal is developing a selective, biased small-molecule agonist intended to activate the signaling pathways responsible for therapeutic effects while avoiding unwanted activity at related receptors. The company says preclinical work has shown high selectivity against MC1R and a favorable safety profile, although those findings still need confirmation in humans.

Selectivity matters because melanocortin receptors influence several biological processes beyond appetite. Rhythm Pharmaceuticals’ approved IMCIVREE, or setmelanotide, has demonstrated that MC4R agonism can produce clinically meaningful weight loss in genetically defined obesity syndromes, but the market is already evolving toward next-generation agents seeking more convenient dosing and different tolerability profiles. Superluminal therefore is not proving that MC4R is druggable. It is trying to prove that its small-molecule design can deliver enough differentiation to compete with therapies already moving quickly.

Rhythm generated $71.3 million of second-quarter 2026 IMCIVREE net product revenue, up 19% sequentially, including $51 million from the United States. FDA approval for acquired hypothalamic obesity in March produced more than 400 patient-start forms from approximately 300 prescribers by June 30, demonstrating both clinical demand and the commercial value of expanding beyond the original genetic indications. Rhythm is also developing weekly injectable RM-718 and oral bivamelagon, so Superluminal may eventually compete not only with today’s IMCIVREE but with a more convenient next generation of MC4R therapies.

Why are Eli Lilly and NVIDIA both backing the same early-stage biotech?

Superluminal’s Hyperloop platform combines protein dynamics, very large-scale virtual screening, generative molecule design, pharmacokinetic and toxicology prediction, and experimental validation. GPCRs are a logical initial target class because they are enormously important in human biology but can be difficult to drug selectively when receptor structures shift between different functional states. Superluminal argues that integrating computational modeling with structural biology can identify molecules that favor particular signaling configurations rather than merely bind the receptor.

That proposition explains NVIDIA’s strategic interest because the discovery process depends heavily on computational methods, while Eli Lilly has an obvious interest in the resulting cardiometabolic medicines. Lilly’s separate 2025 agreement gives it exclusive development and commercialization rights to candidates arising from specified undisclosed GPCR programs after Superluminal delivers compounds meeting predefined criteria. Superluminal can receive up to $1.3 billion through upfront and near-term consideration, equity investment, development and commercial milestones, plus tiered royalties.

The partnership simultaneously validates and complicates Superluminal’s story. Lilly’s willingness to commit milestone economics suggests the platform has attracted sophisticated external scientific diligence, but the most valuable future compounds arising from partnered targets could ultimately belong commercially to Lilly. The wholly owned MC4R candidate therefore carries disproportionate importance because it can demonstrate whether Superluminal can create a medicine and retain control of the economics.

Why does moving into Phase 1 change the way Superluminal should be valued?

Drug-discovery platforms are often difficult to evaluate because investors can admire sophisticated computational capabilities without knowing whether those tools generate medicines that work in humans. Initiating Phase 1 begins to answer that question by exposing the candidate to real pharmacokinetic, tolerability and dose-response testing. A successful study would validate both the individual MC4R program and part of the discovery process that produced it.

Failure would have the opposite effect because Superluminal’s differentiation is built partly around the claim that its platform can design highly selective compounds against challenging GPCR biology. A molecule that produces unexpected off-target effects or inadequate exposure could weaken confidence in the platform more broadly, although one failed candidate would not invalidate every program.

The $60 million financing buys Superluminal the opportunity to produce that evidence without immediately depending on another capital round. It does not de-risk the science. The company is entering a commercially validated rare-obesity category backed by exceptional investors, but it is also entering a market where the incumbent already has approved products, growing sales and next-generation candidates of its own. The first human data will tell investors whether Superluminal has built a genuine MC4R challenger or simply financed an elegant preclinical hypothesis.